



One Evertrust Plaza, Suite 1207
Jersey City, NJ, 07302
Phone: 201-401-1104
Email: celltrionusa@celltrion.com

Date: April 10, 2023

**NOTIFICATION PURSUANT TO
18 V.S.A. § 4637(b)**

Subject: Notification of a new prescription drug

To: The Office of the Attorney General of Vermont

Celltrion USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug pursuant to 18 V.S.A. § 4637(b).

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	Wholesale Acquisition Cost as of the date of Commercial Availability
VEGZELMA (bevacizumab-adcd) INTRAVENOUS 4 ml	72606-0011-01	4/10/2023	\$677.40
VEGZELMA (bevacizumab-adcd) INTRAVENOUS 16ml	72606-0012-01	4/10/2023	\$2709.60

Celltrion USA, Inc. became aware of this reporting requirement after the launch of this product and is aware that an additional 30-day report is due and is currently working on compiling the required information.

Sincerely,

JoonHwan Bae

Chief Operating Officer
Celltrion USA, Inc.